179 related articles for article (PubMed ID: 15268682)
1. Immunotherapy of ovarian cancer with antibodies: a focus on oregovomab.
Berek JS
Expert Opin Biol Ther; 2004 Jul; 4(7):1159-65. PubMed ID: 15268682
[TBL] [Abstract][Full Text] [Related]
2. Oregovomab: anti-CA-125 monoclonal antibody B43.13--AltaRex, B43.13, MAb B43.13, monoclonal antibody B43.13.
Drugs R D; 2006; 7(6):379-83. PubMed ID: 17073521
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy of human ovarian carcinoma with OvaRex MAb-B43.13 in a human-PBL-SCID/BG mouse model.
Schultes BC; Zhang C; Xue LY; Noujaim AA; Madiyalakan R
Hybridoma; 1999 Feb; 18(1):47-55. PubMed ID: 10211788
[TBL] [Abstract][Full Text] [Related]
4. Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer.
Berek J; Taylor P; McGuire W; Smith LM; Schultes B; Nicodemus CF
J Clin Oncol; 2009 Jan; 27(3):418-25. PubMed ID: 19075271
[TBL] [Abstract][Full Text] [Related]
5. The Immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer.
Braly P; Nicodemus CF; Chu C; Collins Y; Edwards R; Gordon A; McGuire W; Schoonmaker C; Whiteside T; Smith LM; Method M
J Immunother; 2009 Jan; 32(1):54-65. PubMed ID: 19307994
[TBL] [Abstract][Full Text] [Related]
6. A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer.
Ehlen TG; Hoskins PJ; Miller D; Whiteside TL; Nicodemus CF; Schultes BC; Swenerton KD
Int J Gynecol Cancer; 2005; 15(6):1023-34. PubMed ID: 16343178
[TBL] [Abstract][Full Text] [Related]
7. CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients.
Gordon AN; Schultes BC; Gallion H; Edwards R; Whiteside TL; Cermak JM; Nicodemus CF
Gynecol Oncol; 2004 Aug; 94(2):340-51. PubMed ID: 15297171
[TBL] [Abstract][Full Text] [Related]
8. Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer.
Berek JS; Taylor PT; Gordon A; Cunningham MJ; Finkler N; Orr J; Rivkin S; Schultes BC; Whiteside TL; Nicodemus CF
J Clin Oncol; 2004 Sep; 22(17):3507-16. PubMed ID: 15337799
[TBL] [Abstract][Full Text] [Related]
9. Current approaches in ovarian cancer vaccines.
Reinartz S; Wagner U
Minerva Ginecol; 2004 Dec; 56(6):515-27. PubMed ID: 15729204
[TBL] [Abstract][Full Text] [Related]
10. Induction of CA125-specific B and T cell responses in patients injected with MAb-B43.13--evidence for antibody-mediated antigen-processing and presentation of CA125 in vivo.
Noujaim AA; Schultes BC; Baum RP; Madiyalakan R
Cancer Biother Radiopharm; 2001 Jun; 16(3):187-203. PubMed ID: 11471484
[TBL] [Abstract][Full Text] [Related]
11. CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5-year follow-up survey to a randomized placebo-controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer.
Berek JS; Taylor PT; Nicodemus CF
J Immunother; 2008; 31(2):207-14. PubMed ID: 18481390
[TBL] [Abstract][Full Text] [Related]
12. Antibody-based immunotherapy for ovarian cancer: where are we at?
Tse BW; Collins A; Oehler MK; Zippelius A; Heinzelmann-Schwarz VA
Ann Oncol; 2014 Feb; 25(2):322-31. PubMed ID: 24285017
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-6 fused to an anti-idiotype antibody in a vaccine increases the specific humoral immune response against CA125+ (MUC-16) ovarian cancer.
Reinartz S; Hombach A; Köhler S; Schlebusch H; Wallwiener D; Abken H; Wagner U
Cancer Res; 2003 Jun; 63(12):3234-40. PubMed ID: 12810653
[TBL] [Abstract][Full Text] [Related]
14. Human monoclonal antibody for ovarian clear cell carcinoma-2, a human monoclonal antibody with antitumor activity against ovarian cancer cells that recognizes CA125-like antigen.
Suzuki N; Tamada Y; Shigirahara K; Suzuki A; Susumu N; Ishida I; Aoki D
Int J Gynecol Cancer; 2008; 18(5):996-1006. PubMed ID: 18028379
[TBL] [Abstract][Full Text] [Related]
15. [Monoclonal anti-idiotype antibodies in immunotherapy of ovarian carcinoma (MAb ACA125) and breast carcinoma (MAb ACA14C5)].
Wagner U; Köhler S; Prietl G; Giffels P; Schmidt-Nicolai S; Schlebusch H; Grünn U; Bender H; Biersack HJ; De Potter C; Krebs D; Wallwiener D
Zentralbl Gynakol; 1999; 121(4):190-5. PubMed ID: 10355096
[TBL] [Abstract][Full Text] [Related]
16. Oregovomab: an investigational agent for the treatment of advanced ovarian cancer.
Pietragalla A; Duranti S; Daniele G; Nero C; Ciccarone F; Lorusso D; Fagotti A; Scambia G
Expert Opin Investig Drugs; 2021 Feb; 30(2):103-110. PubMed ID: 33423551
[No Abstract] [Full Text] [Related]
17. Antigen-specific active immunotherapy for ovarian cancer.
Leffers N; Daemen T; Helfrich W; Boezen HM; Cohlen BJ; Melief K; Nijman HW
Cochrane Database Syst Rev; 2010 Jan; (1):CD007287. PubMed ID: 20091627
[TBL] [Abstract][Full Text] [Related]
18. Biologic and immunologic therapies for ovarian cancer.
Berek JS; Schultes BC; Nicodemus CF
J Clin Oncol; 2003 May; 21(10 Suppl):168s-174s. PubMed ID: 12743131
[TBL] [Abstract][Full Text] [Related]
19. Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer.
Grisham RN; Berek J; Pfisterer J; Sabbatini P
Immunotherapy; 2011 Feb; 3(2):153-62. PubMed ID: 21322756
[TBL] [Abstract][Full Text] [Related]
20. Translational immune correlates of indirect antibody immunization in a randomized phase II study using scheduled combination therapy with carboplatin/paclitaxel plus oregovomab in ovarian cancer patients.
Battaglia A; Buzzonetti A; Fossati M; Scambia G; Fattorossi A; Madiyalakan MR; Mahnke YD; Nicodemus C
Cancer Immunol Immunother; 2020 Mar; 69(3):383-397. PubMed ID: 31897661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
